Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Abdel Wahab, Omar ^b   Fathi, Amir T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; DNA DETERMINATION; EPIGENETICS; GENE MUTATION; HISTONE MODIFICATION; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 80053545678     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/469592     Document Type: Review

References (101)

1. Ducray F., Marie Y., Sanson M., IDH1 and IDH2 mutations in gliomas The The New England Journal of Medicine 2009 360 2248
2. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J. W. M., Wesseling P., Reifenberger G., von Deimling A., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathologica 2009 118 4 469 474
3. Parsons D. W., Jones S., Zhang X., Lin J. C. H., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I. M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K. N., Shinjo S. M. O., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W., An integrated genomic analysis of human glioblastoma multiforme Science 2008 321 5897 1807 1812
4. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., Hallani S. E., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J. Y., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas Journal of Clinical Oncology 2009 27 25 4150 4154
5. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H., IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas American Journal of Pathology 2009 174 4 1149 1153
6. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T., Analysis of IDH1 and IDH2 mutations in Japanese glioma patients Cancer Science 2009 100 10 1996 1998
7. Mardis E. R., Ding L., Dooling D. J., Larson D. E., McLellan M. D., Chen K., Koboldt D. C., Fulton R. S., Delehaunty K. D., McGrath S. D., Fulton L. A., Locke D. P., Magrini V. J., Abbott R. M., Vickery T. L., Reed J. S., Robinson J. S., Wylie T., Smith S. M., Carmichael L., Eldred J. M., Harris C. C., Walker J., Peck J. B., Du F., Dukes A. F., Sanderson G. E., Brummett A. M., Clark E., McMichael J. F., Meyer R. J., Schindler J. K., Pohl C. S., Wallis J. W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M. E., Ivy J. V., Kalicki J., Elliott G., Ries R. E., Payton J. E., Westervelt P., Tomasson M. H., Watson M. A., Baty J., Heath S., Shannon W. D., Nagarajan R., Link D. C., Walter M. J., Graubert T. A., DiPersio J. F., Wilson R. K., Ley T. J., Recurring mutations found by sequencing an acute myeloid leukemia genome The New England Journal of Medicine 2009 361 11 1058 1066
8. Tefferi A., Lasho T. L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., Pieri L., Finke C. M., Kilpivaara O., Wadleigh M., Mai M., McClure R. F., Gilliland D. G., Levine R. L., Pardanani A., Vannucchi A. M., IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis Leukemia 2010 24 7 1302 1309
9. Gross S., Cairns R. A., Minden M. D., Driggers E. M., Bittinger M. A., Jang H. G., Sasaki M., Jin S., Schenkein D. P., Su S. M., Dang L., Fantin V. R., Mak T. W., Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations Journal of Experimental Medicine 2010 207 2 339 344
10. Abbas S., Lugthart S., Kavelaars F. G., Schelen A., Koenders J. E., Zeilemaker A., Van Putten W. J. L., Rijneveld A. W., Lwenberg B., Valk P. J. M., Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value Blood 2010 116 12 2122 2126
11. Boissel N., Nibourel O., Renneville A., Gardin C., Reman O., Contentin N., Bordessoule D., Pautas C., de Revel T., Quesnel B., Huchette P., Philippe N., Geffroy S., Terre C., Thomas X., Castaigne S., Dombret H., Preudhomme C., Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the acute leukemia French association group Journal of Clinical Oncology 2010 28 23 3717 3723
12. Marcucci G., Maharry K., Wu Y. Z., Radmacher M. D., Mrzek K., Margeson D., Holland K. B., Whitman S. P., Becker H., Schwind S., Metzeler K. H., Powell B. L., Carter T. H., Kolitz J. E., Wetzler M., Carroll A. J., Baer M. R., Caligiuri M. A., Larson R. A., Bloomfield C. D., IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study Journal of Clinical Oncology 2010 28 14 2348 2355
13. Paschka P., Schlenk R. F., Gaidzik V. I., Habdank M., Krnke J., Bullinger L., Spth D., Kayser S., Zucknick M., Gtze K., Horst H. A., Germing U., Dhner H., Dhner K., IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication Journal of Clinical Oncology 2010 28 22 3636 3643
14. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T., IDH1 mutations are detected in 6.6 of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status Blood 2010 116 25 5486 5496
15. Ward P. S., Patel J., Wise D. R., Abdel-Wahab O., Bennett B. D., Coller H. A., Cross J. R., Fantin V. R., Hedvat C. V., Perl A. E., Rabinowitz J. D., Carroll M., Su S. M., Sharp K. A., Levine R. L., Thompson C. B., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting -ketoglutarate to 2-hydroxyglutarate Cancer Cell 2010 17 3 225 234
16. Yan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G. J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K. W., Velculescu V. E., Vogelstein B., Bigner D. D., IDH1 and IDH2 mutations in gliomas The New England Journal of Medicine 2009 360 8 765 773
17. Dang L., White D. W., Gross S., Bennett B. D., Bittinger M. A., Driggers E. M., Fantin V. R., Jang H. G., Jin S., Keenan M. C., Marks K. M., Prins R. M., Ward P. S., Yen K. E., Liau L. M., Rabinowitz J. D., Cantley L. C., Thompson C. B., Vander Heiden M. G., Su S. M., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 2009 462 7274 739 744
18. Reitman Z. J., Parsons D. W., Yan H., IDH1 and IDH2: not your typical oncogenes Cancer Cell 2010 17 3 215 216
19. Reitman Z. J., Yan H., Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism Journal of the National Cancer Institute 2010 102 13 932 941
20. Klker S., Pawlak V., Ahlemeyer B., Okun J. G., Hrster F., Mayatepek E., Krieglstein J., Hoffmann G. F., Khr G., NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria European Journal of Neuroscience 2002 16 1 21 28 (Pubitemid 35463594)
21. Latini A., Scussiato K., Rosa R. B., Llesuy S., Bell-Klein A., Dutra-Filho C. S., Wajner M., D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats European Journal of Neuroscience 2003 17 10 2017 2022 (Pubitemid 36713962)
22. Frezza C., Tennant D. A., Gottlieb E., IDH1 mutations in gliomas: when an enzyme loses its grip Cancer Cell 2010 17 1 7 9
23. Figueroa M. E., Abdel-Wahab O., Lu C., Ward P. S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H. F., Tallman M. S., Sun Z., Wolniak K., Peeters J. K., Liu W., Choe S. E., Fantin V. R., Paietta E., Lwenberg B., Licht J. D., Godley L. A., Delwel R., Valk P. J. M., Thompson C. B., Levine R. L., Melnick A., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 2010 18 6 553 567
24. Boultwood J., Wainscoat J. S., Gene silencing by DNA methylation in haematological malignancies British Journal of Haematology 2007 138 1 3 11 (Pubitemid 46889779)
25. Leone G., Teofili L., Voso M. T., Lbbert M., DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias Haematologica 2002 87 12 1324 1341 (Pubitemid 36005306)
26. Figueroa M. E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P. J., Schifano E., Booth J., van Putten W., Skrabanek L., Campagne F., Mazumdar M., Greally J. M., Valk P. J. M., Lwenberg B., Delwel R., Melnick A., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia Cancer Cell 2010 17 1 13 27
27. Gore S. D., Baylin S., Sugar E., Carraway H., Miller C. B., Carducci M., Grever M., Galm O., Dauses T., Karp J. E., Rudek M. A., Zhao M., Smith B. D., Manning J., Jiemjit A., Dover G., Mays A., Zwiebel J., Murgo A., Weng L. J., Herman J. G., Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Research 2006 66 12 6361 6369
28. Khan R., Schmidt-Mende J., Karimi M., Gogvadze V., Hassan M., Ekstrm T. J., Zhivotovsky B., Hellstrm-Lindberg E., Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells Experimental Hematology 2008 36 2 149 157
29. Lugthart S., Figueroa M. E., Bindels E., Skrabanek L., Valk P. J. M., Li Y., Meyer S., Erpelinck-Verschueren C., Greally J., Lwenberg B., Melnick A., Delwel R., Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1 Blood 2011 117 1 234 241
30. Ito S., D'Alessio A. C., Taranova O. V., Hong K., Sowers L. C., Zhang Y., Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 2010 466 7310 1129 1133
31. Tahiliani M., Koh K. P., Shen Y., Pastor W. A., Bandukwala H., Brudno Y., Agarwal S., Iyer L. M., Liu D. R., Aravind L., Rao A., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 2009 324 5929 930 935
32. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S. H., Ito S., Yang C., Wang P., Xiao M. T., Liu L. X., Jiang W. Q., Liu J., Zhang J. Y., Wang B., Frye S., Zhang Y., Xu Y. H., Lei Q. Y., Guan K. L., Zhao S. M., Xiong Y., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of -ketoglutarate-dependent dioxygenases Cancer Cell 2011 19 1 17 30
33. Wang Y., Wysocka J., Sayegh J., Lee Y. H., Pertin J. R., Leonelli L., Sonbuchner L. S., McDonald C. H., Cook R. G., Dou Y., Roeder R. G., Clarke S., Stallcup M. R., Allis C. D., Coonrod S. A., Human PAD4 regulates histone arginine methylation levels via demethylimination Science 2004 306 5694 279 283 (Pubitemid 39336873)
34. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J. R., Cole P. A., Casero R. A., Shi Y., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 2004 119 7 941 953 (Pubitemid 40037608)
35. Klose R. J., Yamane K., Bae Y., Zhang D., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y., The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36 Nature 2006 442 7100 312 316 (Pubitemid 44114907)
36. Yamane K., Toumazou C., Tsukada Y. I., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y., JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor Cell 2006 125 3 483 495
37. Seward D. J., Cubberley G., Kim S., Schonewald M., Zhang L., Tripet B., Bentley D. L., Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins Nature Structural and Molecular Biology 2007 14 3 240 242 (Pubitemid 46355570)
38. Agger K., Cloos P. A. C., Christensen J., Pasini D., Rose S., Rappsilber J., Issaeva I., Canaani E., Salcini A. E., Helin K., UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development Nature 2007 449 7163 731 734 (Pubitemid 47552088)
39. Chang B., Chen Y., Zhao Y., Bruick R. K., JMJD6 is a histone arginine demethylase Science 2007 318 5849 444 447 (Pubitemid 47614528)
40. Schlenk R. F., Dhner K., Krauter J., Frhling S., Corbacioglu A., Bullinger L., Habdank M., Spth D., Morgan M., Benner A., Schlegelberger B., Heil G., Ganser A., Dhner H., Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia The New England Journal of Medicine 2008 358 18 1909 1918 (Pubitemid 351620111)
41. Frhling S., Schlenk R. F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Dhner H., Dhner K., Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm Blood 2002 100 13 4372 4380 (Pubitemid 35434129)
42. Schnittger S., Schoch C., Kern W., Mecucci C., Tschulik C., Martelli M. F., Haferlach T., Hiddemann W., Falini B., Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 2005 106 12 3733 3739 (Pubitemid 41739006)
43. Dhner K., Schlenk R. F., Habdank M., Scholl C., Rcker F. G., Corbacioglu A., Bullinger L., Frhling S., Dhner H., Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 2005 106 12 3740 3746 (Pubitemid 41739007)
44. Frhling S., Schlenk R. F., Stolze I., Bihlmayr J., Benner A., Kreitmeier S., Tobis K., Dhner H., Dhner K., CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations Journal of Clinical Oncology 2004 22 4 624 633 (Pubitemid 41095065)
45. Preudhomme C., Sagot C., Boissel N., Cayuela J. M., Tigaud I., De Botton S., Thomas X., Raffoux E., Lamandin C., Castaigne S., Fenaux P., Dombret H., Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Blood 2002 100 8 2717 2723
46. Green C. L., Evans C. M., Hills R. K., Burnett A. K., Linch D. C., Gale R. E., The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status Blood 2010 116 15 2779 2782
47. Schnittger S., Haferlach C., Alpermann T., Kern W., Haferlach T., IDH mutations can be detected In 28.7 of all normal karyotype AML and have unfavourable impact on the NPM1?ITD- genotype Blood 2010 116. ASH Annual Meeting Abstracts, Abstract 102
48. Ravandi F., Patel K. P., Luthra R., Prognostic significance of mutations in isocitrate dehydrogenase (IDH) enzyme isoforms 1 and 2 and single nucleotide polymorphisms (SNP) in IDH1, in patients with acute myeloid leukemia treated with high dose cytarabine and idarubicin induction Blood 2010 116. ASH Annual Meeting Abstracts, Abstract 2706
49. Caramazza D., Lasho T., Finke C., IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia Blood 2010 116. ASH Annual Meeting Abstracts, Abstract 4009
50. Delhommeau F., Dupont S., Valle V. D., James C., Trannoy S., Massé A., Kosmider O., Le Couedic J. P., Robert F., Alberdi A., Lécluse Y., Plo I., Dreyfus F. J., Marzac C., Casadevall N., Lacombe C., Romana S. P., Dessen P., Soulier J., Viguié F., Fontenay M., Vainchenker W., Bernard O. A., Mutation in TET2 in myeloid cancers The New England Journal of Medicine 2009 360 22 2289 2301
51. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J., Kilpivaara O., Bhat R., Huberman K., Thomas S., Dolgalev I., Heguy A., Paietta E., Le Beau M. M., Beran M., Tallman M. S., Ebert B. L., Kantarjian H. M., Stone R. M., Gilliland D. G., Crispino J. D., Levine R. L., Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 2009 114 1 144 147
52. Jankowska A. M., Szpurka H., Tiu R. V., Makishima H., Afable M., Huh J., O'Keefe C. L., Ganetzky R., McDevitt M. A., Maciejewski J. P., Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms Blood 2009 113 25 6403 6410
53. Tefferi A., Pardanani A., Lim K. H., Abdel-Wahab O., Lasho T. L., Patel J., Gangat N., Finke C. M., Schwager S., Mullally A., Li C. Y., Hanson C. A., Mesa R., Bernard O., Delhommeau F., Vainchenker W., Gilliland D. G., Levine R. L., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis Leukemia 2009 23 5 905 911
54. Langemeijer S. M. C., Kuiper R. P., Berends M., Knops R., Aslanyan M. G., Massop M., Stevens-Linders E., Van Hoogen P., Van Kessel A. G., Raymakers R. A. P., Kamping E. J., Verhoef G. E., Verburgh E., Hagemeijer A., Vandenberghe P., de Witte T., van Der Reijden B. A., Jansen J. H., Acquired mutations in TET2 are common in myelodysplastic syndromes Nature Genetics 2009 41 7 838 842
55. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., Heguy A., Bueso-Ramos C., Kantarjian H., Levine R. L., Verstovsek S., Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias Cancer Research 2010 70 2 447 452
56. Guo J. U., Su Y., Zhong C., Ming G. L., Song H., Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain Cell 2011 145 3 423 434
57. Ko M., Huang Y., Jankowska A. M., Pape U. J., Tahiliani M., Bandukwala H. S., An J., Lamperti E. D., Koh K. P., Ganetzky R., Liu X. S., Aravind L., Agarwal S., MacIejewski J. P., Rao A., Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 2010 468 7325 839 843
58. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., Quesnel B., Fenaux P., Bastie J. N., Beyne-Rauzy O., Stamatoulas A., Dreyfus F., Ifrah N., De Botton S., Vainchenker W., Bernard O. A., Birnbaum D., Fontenay M., Solary E., TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 2009 94 12 1676 1681
59. Nibourel O., Kosminder O., Cheok M., Association of TET2 alterations with NPM1 mutations and prognostic value in de novo Acute Myeloid Leukemia (AML) Blood 2009 114 22
60. Gaidzik V., Schlenk R. F., Paschka P., TET2 mutations in Acute Myeloid Leukemia (AML): results on 783 patients treated within the AML HD98A study of the AML Study Group (AMLSG) Blood 2010 116
61. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., Viguié F., Quesnel B., Beyne-Rauzy O., Solary E., Vey N., Hunault-Berger M., Fenaux P., Mansat-De Mas V., Delabesse E., Guardiola P., Lacombe C., Vainchenker W., Preudhomme C., Dreyfus F., Bernard O. A., Birnbaum D., Fontenay M., TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 2009 114 15 3285 3291
62. Metzeler K. H., Maharry K., Radmacher M. D., Mrzek K., Margeson D., Becker H., Curfman J., Holland K. B., Schwind S., Whitman S. P., Wu Y. Z., Blum W., Powell B. L., Carter T. H., Wetzler M., Moore J. O., Kolitz J. E., Baer M. R., Carroll A. J., Larson R. A., Caligiuri M. A., Marcucci G., Bloomfield C. D., TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study Journal of Clinical Oncology 2011 29 10 1373 1381
63. Ley T. J., Ding L., Walter M. J., McLellan M. D., Lamprecht T., Larson D. E., Kandoth C., Payton J. E., Baty J., Welch J., Harris C. C., Lichti C. F., Townsend R. R., Fulton R. S., Dooling D. J., Koboldt D. C., Schmidt H., Zhang Q., Osborne J. R., Lin L., O'Laughlin M., McMichael J. F., Delehaunty K. D., McGrath S. D., Fulton L. A., Magrini V. J., Vickery T. L., Hundal J., Cook L. L., Conyers J. J., Swift G. W., Reed J. P., Alldredge P. A., Wylie T., Walker J., Kalicki J., Watson M. A., Heath S., Shannon W. D., Varghese N., Nagarajan R., Westervelt P., Tomasson M. H., Link D. C., Graubert T. A., DiPersio J. F., Mardis E. R., Wilson R. K., DNMT3A mutations in acute myeloid leukemia The New England Journal of Medicine 2010 363 25 2424 2433
64. Yamashita Y., Yuan J., Suetake I., Suzuki H., Ishikawa Y., Choi Y. L., Ueno T., Soda M., Hamada T., Haruta H., Takada S., Miyazaki Y., Kiyoi H., Ito E., Naoe T., Tomonaga M., Toyota M., Tajima S., Iwama A., Mano H., Array-based genomic resequencing of human leukemia Oncogene 2010 29 25 3723 3731
65. Yan X. J., Xu J., Gu Z. H., Pan C. M., Lu G., Shen Y., Shi J. Y., Zhu Y. M., Tang L., Zhang X. W., Liang W. X., Mi J. Q., Song H. D., Li K. Q., Chen Z., Chen S. J., Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia Nature Genetics 2011 43 4 309 315
66. Walter M. J., Ding L., Shen D., Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. In press
67. Abdel-Wahab O., Pardanani A., Rampal R., Lasho T. L., Levine R. L., Tefferi A., DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. In press
68. Morin R. D., Johnson N. A., Severson T. M., Mungall A. J., An J., Goya R., Paul J. E., Boyle M., Woolcock B. W., Kuchenbauer F., Yap D., Humphries R. K., Griffith O. L., Shah S., Zhu H., Kimbara M., Shashkin P., Charlot J. F., Tcherpakov M., Corbett R., Tam A., Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H., Birol I., Schein J., Moore R., Holt R., Horsman D. E., Connors J. M., Jones S., Aparicio S., Hirst M., Gascoyne R. D., Marra M. A., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nature Genetics 2010 42 2 181 185
69. Abdel-Wahab O., Pardanani A., Patel J., Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. In press
70. Ernst T., Chase A. J., Score J., Hidalgo-Curtis C. E., Bryant C., Jones A. V., Waghorn K., Zoi K., Ross F. M., Reiter A., Hochhaus A., Drexler H. G., Duncombe A., Cervantes F., Oscier D., Boultwood J., Grand F. H., Cross N. C. P., Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nature Genetics 2010 42 8 722 726
71. Nikoloski G., Langemeijer S. M. C., Kuiper R. P., Knops R., Massop M., Tnnissen E. R. L. T. M., Van Der Heijden A., Scheele T. N., Vandenberghe P., De Witte T., Van Der Reijden B. A., Jansen J. H., Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nature Genetics 2010 42 8 665 667
72. Viré E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J. M., Bollen M., Esteller M., Di Croce L., De Launoit Y., Fuks F., The Polycomb group protein EZH2 directly controls DNA methylation Nature 2006 439 7078 871 874 (Pubitemid 43255707)
73. Dhner K., Brown J., Hehmann U., Hetzel C., Stewart J., Lowther G., Scholl C., Frhling S., Cuneo A., Tsui L. C., Lichter P., Scherer S. W., Dhner H., Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders Blood 1998 92 11 4031 4035 (Pubitemid 28544315)
74. Le Beau M. M., Espinosa R. III, Davis E. M., Eisenbart J. D., Larson R. A., Green E. D., Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases Blood 1996 88 6 1930 1935 (Pubitemid 26307892)
75. Garcia-Manero G., Gore S. D., Cogle C. R., Evaluation of oral azacitidine using extended treatment schedules: a phase I study Blood 2010 116
76. Yang A. S., Doshi K. D., Choi S. W., Mason J. B., Mannari R. K., Gharybian V., Luna R., Rashid A., Shen L., Estecio M. R. H., Kantarjian H. M., Garcia-Manero G., Issa J. P. J., DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia Cancer Research 2006 66 10 5495 5503 (Pubitemid 43844978)
77. Zhou L., Cheng X., Connolly B. A., Dickman M. J., Hurd P. J., Hornby D. P., Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases Journal of Molecular Biology 2002 321 4 591 599 (Pubitemid 36124798)
78. Cheng J. C., Matsen C. B., Gonzales F. A., Ye W., Greer S., Marquez V. E., Jones P. A., Selker E. U., Inhibition of DNA methylation and reactivation of silenced genes by zebularine Journal of the National Cancer Institute 2003 95 5 399 409 (Pubitemid 36395260)
79. Cheng J. C., Yoo C. B., Weisenberger D. J., Chuang J., Wozniak C., Liang G., Marquez V. E., Greer S., Orntoft T. F., Thykjaer T., Jones P. A., Preferential response of cancer cells to zebularine Cancer Cell 2004 6 2 151 158 (Pubitemid 39485687)
80. Davis A. J., Gelmon K. A., Siu L. L., Moore M. J., Britten C. D., Mistry N., Klamut H., D'Aloisio S., MacLean M., Wainman N., Ayers D., Firby P., Besterman J. M., Reid G. K., Eisenhauer E. A., Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks Investigational New Drugs 2003 21 1 85 97 (Pubitemid 36628488)
81. Stewart D. J., Donehower R. C., Eisenhauer E. A., Wainman N., Shah A. K., Bonfils C., MacLeod A. R., Besterman J. M., Reid G. K., A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Annals of Oncology 2003 14 5 766 774 (Pubitemid 36621778)
82. Klisovic R. B., Stock W., Cataland S., Klisovic M. I., Liu S., Blum W., Green M., Odenike O., Godley L., Vanden Burgt J., Van Laar E., Cullen M., Macleod A. R., Besterman J. M., Reid G. K., Byrd J. C., Marcucci G., A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia Clinical Cancer Research 2008 14 8 2444 2449 (Pubitemid 351551079)
83. Winquist E., Knox J., Ayoub J. P., Wood L., Wainman N., Reid G. K., Pearce L., Shah A., Eisenhauer E., Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study Investigational New Drugs 2006 24 2 159 167 (Pubitemid 43723908)
84. Brueckner B., Boy R. G., Siedlecki P., Musch T., Kliem H. C., Zielenkiewicz P., Suhai S., Wiessler M., Lyko F., Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Research 2005 65 14 6305 6311 (Pubitemid 40994416)
85. Kuck D., Singh N., Lyko F., Medina-Franco J. L., Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation Bioorganic and Medicinal Chemistry 2010 18 2 822 829
86. Itzykson R., Kosmider O., Cluzeau T., Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. In press
87. Pollyea D. A., Raval A., Kusler B., Gotlib J. R., Alizadeh A. A., Mitchell B. S., Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors Journal of Hematology Oncology 2010
88. Krivtsov A. V., Armstrong S. A., MLL translocations, histone modifications and leukaemia stem-cell development Nature Reviews Cancer 2007 7 11 823 833 (Pubitemid 350006257)
89. Wang G. G., Cai L., Pasillas M. P., Kamps M. P., NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis Nature Cell Biology 2007 9 7 804 812 (Pubitemid 47019467)
90. Meyer C., Kowarz E., Hofmann J., Renneville A., Zuna J., Trka J., Ben Abdelali R., Macintyre E., De Braekeleer E., De Braekeleer M., Delabesse E., de Oliveira M. P., Cavé H., Clappier E., van Dongen J. J. M., Balgobind B. V., van den Heuvel-Eibrink M. M., Beverloo H. B., Panzer-Grmayer R., Teigler-Schlegel A., Harbott J., Kjeldsen E., Schnittger S., Koehl U., Gruhn B., Heidenreich O., Chan L. C., Yip S. F., Krzywinski M., Eckert C., Mricke A., Schrappe M., Alonso C. N., Schfer B. W., Krauter J., Lee D. A., zur Stadt U., Te Kronnie G., Sutton R., Izraeli S., Trakhtenbrot L., Lo Nigro L., Tsaur G., Fechina L., Szczepanski T., Strehl S., Ilencikova D., Molkentin M., Burmeister T., Dingermann T., Klingebiel T., Marschalek R., New insights to the MLL recombinome of acute leukemias Leukemia 2009 23 8 1490 1499
91. Jo S. Y., Granowicz E. M., Maillard I., Thomas D., Hess J. L., Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation Blood 2011 117 18 4759 4768
92. Bernt K., Zhu N., Faber J., Demonstration of a role for Dot1l in MLL-rearranged leukemia using a conditional loss of function model Blood 2010 116
93. Pollock R., Daigle S. R., Olhava E. J., Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Blood 2010 116
94. Krivtsov A. V., Feng Z., Lemieux M. E., Faber J., Vempati S., Sinha A. U., Xia X., Jesneck J., Bracken A. P., Silverman L. B., Kutok J. L., Kung A. L., Armstrong S. A., H3K79 methylation profiles define murine and human MLL-AF4 leukemias Cancer Cell 2008 14 5 355 368
95. Bursen A., Schwabe K., Rster B., Henschler R., Ruthardt M., Dingermann T., Marschalek R., The AF4 MLL fusion protein is capable of inducing ALL in mice without requirement of MLL AF4 Blood 2010 115 17 3570 3579
96. Benedikt A., Baltruschat S., Scholz B., Bursen A., Arrey T. N., Meyer B., Varagnolo L., Mller A. M., Karas M., Dingermann T., Marschalek R., The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures Leukemia 2010 25 135 144
97. Nguyen A. T., Xiao B., Neppl R. L., Kallin E. M., Li J., Chen T., Wang D. Z., Xiao X., Zhang Y., DOT1L regulates dystrophin expression and is critical for cardiac function Genes and Development 2011 25 3 263 274
98. Jankowska A., Makishima H., Tiu R. V., Mutational spectrum in chronic myelomonocytic leukemia includes genes associated with epigenetic regulation such as UTX and EZH2 Blood 2010 116
99. Allan M., Manku S., Therrien E., Nguyen N., Styhler S., Robert M. F., Goulet A. C., Petschner A. J., Rahil G., Robert MacLeod A., Déziel R., Besterman J. M., Nguyen H., Wahhab A., N-benzyl-1-heteroaryl-3-(trifluoromethyl) -1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1) Bioorganic and Medicinal Chemistry Letters 2009 19 4 1218 1223
100. Eeckhoute J., Keeton E. K., Lupien M., Krum S. A., Carroll J. S., Brown M., Positive cross-regulatory loop ties GATA-3 to estrogen receptor expression in breast cancer Cancer Research 2007 67 13 6477 6483 (Pubitemid 47037533)
101. Kim Y. R., Lee B. K., Park R. Y., Nguyen N. T. X., Bae J. A., Kwon D. D., Jung C., Differential CARM1 expression in prostate and colorectal cancers BioMed Central Cancer 2010 10 197